Arena Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arena Pharmaceuticals, Inc.
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Philips will pay $635m for the Massachusetts-based developer of a platform that connects medical devices and electronic medical records in hospitals.
- Other Names / Subsidiaries
- Beacon Discovery Inc.